Home › Calculator › MTNB Dividend Calculator 2026
MTNB Dividend DRIP Calculator 2026
828.50% YieldHealthcareMatinas BioPharma Holdings, Inc. · AMEX
Price: $0.24 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When MTNB pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your MTNB snowball 📈
$10,000 in MTNB → $46507.29M in 10 years · $3,458,202,685.72/month
About Matinas BioPharma Holdings, Inc. (MTNB) — Dividend Analysis 2026
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
Compare MTNB with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full MTNB DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MTNB position with:
🌍 MTNB Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold MTNB.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 828.50% | 825.70% | $82,850 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 704.23% | 701.43% | $70,423 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 662.80% | 660.00% | $66,280 / yr |
| 🇬🇧 UK ISA | 0% | 828.50% | 825.70% | $82,850 / yr |
| 🇬🇧 UK Taxable | 8.75% | 756.01% | 753.21% | $75,601 / yr |
| 🇨🇦 TFSA | 0% | 828.50% | 825.70% | $82,850 / yr |
| 🇨🇦 CA Taxable | 25% | 621.38% | 618.58% | $62,138 / yr |
| 🇦🇺 Super (pension) | 15% | 704.23% | 701.43% | $70,423 / yr |
| 🇦🇺 AU Taxable | 30% | 579.95% | 577.15% | $57,995 / yr |
| 🇩🇪 DE Taxable | 26.375% | 609.98% | 607.18% | $60,998 / yr |
| 🇫🇷 FR Taxable | 30% | 579.95% | 577.15% | $57,995 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 MTNB Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 MTNB Dividend Payment Schedule
MTNB pays quarterly — 4 times per year. Next ex-div: TBD.
📊 MTNB vs Healthcare Benchmarks
How MTNB compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MTNB sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ MTNB Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2025-04-30 | 11,600 | $0.59 | $6.8K | ||
| A-Award | 2025-04-30 | 11,600 | $0.59 | $6.8K | ||
| A-Award | 2025-04-30 | 11,600 | $0.59 | $6.8K | ||
| A-Award | 2025-04-30 | 70,100 | $0.59 | $41.4K | ||
| A-Award | 2025-04-30 | 11,600 | $0.59 | $6.8K | ||
| Other | 2025-02-13 | 2,399,318 | — | — | ||
| Other | 2025-02-13 | 4,798,636 | — | — | ||
| Buy | 2025-04-08 | 2,399,318 | $0.64 | $1.55M | ||
| Buy | 2025-04-08 | 703 | $0.59 | $412.00 | ||
| Buy | 2025-04-08 | 1,679,182 | $0.64 | $1.08M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MTNB dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Matinas BioPharma Holdings, Inc. (MTNB) is currently trading at $0.24, trading near its 52-week low. The current dividend yield is 828.50% based on an annual payout of $2.00 per share.
MTNB (Matinas BioPharma Holdings, Inc.) — 828.50% Dividend Yield Analysis
Matinas BioPharma Holdings, Inc. (MTNB) is a healthcare stock currently trading at $0.24 with a dividend yield of 828.50%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, MTNB has grown its dividend at a compound annual rate of 50.0%.
- Above-average yield (828.50%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest MTNB News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.